Roivant Sciences Ltd. (NASDAQ:ROIV) Shares Bought by KBC Group NV

KBC Group NV raised its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 58.2% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 15,874 shares of the company’s stock after acquiring an additional 5,839 shares during the quarter. KBC Group NV’s holdings in Roivant Sciences were worth $188,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Dimensional Fund Advisors LP purchased a new stake in Roivant Sciences during the second quarter worth approximately $2,671,000. Sei Investments Co. raised its holdings in Roivant Sciences by 64.3% during the second quarter. Sei Investments Co. now owns 22,151 shares of the company’s stock worth $234,000 after purchasing an additional 8,667 shares in the last quarter. Squarepoint Ops LLC lifted its position in shares of Roivant Sciences by 14.7% during the 2nd quarter. Squarepoint Ops LLC now owns 47,579 shares of the company’s stock worth $503,000 after buying an additional 6,091 shares during the last quarter. Cetera Investment Advisers boosted its holdings in shares of Roivant Sciences by 39.4% in the 2nd quarter. Cetera Investment Advisers now owns 100,288 shares of the company’s stock valued at $1,060,000 after buying an additional 28,324 shares in the last quarter. Finally, Handelsbanken Fonder AB grew its position in shares of Roivant Sciences by 67.7% in the 3rd quarter. Handelsbanken Fonder AB now owns 191,409 shares of the company’s stock valued at $2,209,000 after buying an additional 77,300 shares during the last quarter. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Roivant Sciences Stock Performance

Shares of ROIV opened at $10.97 on Thursday. Roivant Sciences Ltd. has a fifty-two week low of $9.76 and a fifty-two week high of $13.06. The firm has a 50-day simple moving average of $11.58 and a 200-day simple moving average of $11.60. The company has a market capitalization of $7.99 billion, a price-to-earnings ratio of 1.94 and a beta of 1.25.

Analyst Upgrades and Downgrades

ROIV has been the subject of a number of research reports. Cantor Fitzgerald raised shares of Roivant Sciences to a “strong-buy” rating in a research report on Thursday, January 30th. HC Wainwright reissued a “buy” rating and issued a $18.00 target price on shares of Roivant Sciences in a report on Wednesday, November 13th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $17.93.

Insider Buying and Selling at Roivant Sciences

In related news, COO Eric Venker sold 100,000 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $11.28, for a total value of $1,128,000.00. Following the completion of the sale, the chief operating officer now owns 732,294 shares in the company, valued at $8,260,276.32. This trade represents a 12.01 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Sciences Ltd. Roivant acquired 16,845,010 shares of the stock in a transaction on Monday, January 13th. The stock was acquired at an average cost of $20.00 per share, for a total transaction of $336,900,200.00. Following the acquisition, the director now directly owns 96,650,341 shares in the company, valued at $1,933,006,820. This represents a 21.11 % increase in their position. The disclosure for this purchase can be found here. Insiders sold a total of 1,942,629 shares of company stock valued at $23,034,486 in the last ninety days. Insiders own 7.90% of the company’s stock.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.